The healthcare industry is increasingly becoming resource constrained. A new generation of products and technological advances are making it challenging for companies to seek out the right investment opportunities for their businesses – investment opportunities that satisfy both societal and shareholder needs.
The social, demographic and economic context in which the healthcare and life science ecosystem operates is changing drastically.
From new market entrants and regulatory reforms to the digital health revolution and the growing challenge of an ageing population and chronic diseases, healthcare societal decision makers and life science industry participants must explore a new course to address the changing climate for healthcare — one driven by patients and focused on health outcomes.
Looking ahead, these challenges are set to become even more pronounced but also to present numerous opportunities and posed to change healthcare for the better. Ecosystem participants that anticipate and adapt to these changes will have a greater competitive edge in the years ahead.
The Healthcare and Life Science ecosystem is notable for the political impact of the everyday operations of the constituent businesses and organizations. Whether it is innovative science being weighed against compliance and risk or the pricing of new treatments that are life altering but ultimately unaffordable, there is a need to strike a balance between benefit, cost, risk, and innovation.
In conclusion, we see a market that continues to reward innovation, but that has become wary of the cost of that innovation. Where risk and benefit is becoming a more common discussion in both market and research discussions and where the line between Drug, Device, and Diagnostic is becoming more and more blurred.